tbuckley/cabot-search huggingface dataset:
Limitations of Ejection Fraction for Prediction of Sudden Death Risk in Patients With Coronary Artery Disease
Authors: Alfred E. Buxton, Kerry L. Lee, Gail E. Hafley, Luis A. Pires, John D. Fisher, Michael R. Gold, Mark E. Josephson, Michael H. Lehmann, Eric N. Prystowsky
Journal: Journal of the American College of Cardiology (2007)
연구논문 : 간세포암종 파열 환자의 임상양상 및 예후인자에 관한 연구
Authors: 김영일 ( Young Il Kim ), 기호석 ( Ho Seok Ki ), 김민형 ( Min Hyoung Kim ), 조동근 ( Dong Keun Cho ), 조성범 ( Sung Bum Cho ), 주영은 ( Young Eun Joo ), 김현수 ( Hyun Soo Kim ), 최성규 ( Sung Kyu Choi ), 류종선 ( Jong Sun Rew )
Journal: Clinical and Molecular Hepatology (2009)
Light chain amyloidosis induced inflammatory changes in cardiomyocytes and adipose-derived mesenchymal stromal cells
Authors: Torri L. Jordan, Khansaa Maar, Keely R. Redhage, Pinaki Misra, Luis M. Blancas-Mejia, Christopher J. Dick, Jonathan S. Wall, Angela Williams, Allan B. Dietz, Andre J. van Wijnen, Yi Lin, Marina Ramirez-Alvarado
Journal: Leukemia (2019)
The impact of airborne pollution on atopic dermatitis: a literature review
Authors: A.J. Hendricks, L.F. Eichenfield, V.Y. Shi
Journal: British Journal of Dermatology (2019)

The increasing prevalence of atopic dermatitis (AD) parallels a global rise in industrialization and urban living over recent decades. This shift in lifestyle is accompanied by greater cutaneous exposure to environmental pollutants during the course of daily activities. The objectives of this review are to highlight the effects of airborne pollution on epidermal barrier function, examine evidence on the relationship between pollutants and AD, synthesize a proposed mechanism for pollution‐induced exacerbation of AD, and identify potential methods for the reduction and prevention of pollutant‐induced skin damage. The literature review was done by searching the PubMed, Embase and Google Scholar databases. Inclusion criteria were in vitro and animal studies, clinical trials and case series. Non‐English‐language publications, review articles and case reports were excluded. Pollutants induce cutaneous oxidative stress and have been shown to damage skin barrier integrity by altering transepidermal water loss, inflammatory signalling, stratum corneum pH and the skin microbiome. AD represents a state of inherent barrier dysfunction, and both long‐ and short‐term pollutant exposure have been linked to exacerbation of AD symptoms and increased AD rates in population studies. Airborne pollutants have a detrimental effect on skin barrier integrity and AD symptoms, and appear to pose a multifaceted threat in AD through several parallel mechanisms, including oxidative damage, barrier dysfunction, immune stimulation and propagation of the itch–scratch cycle. Future research is needed to elucidate specific mechanisms of pollution‐induced epidermal barrier dysfunction and to identify efficacious methods of skin barrier repair and protection against pollutant‐driven damage.
Highly Active Antiretroviral Therapy and Incidence of Cancer in Human Immunodeficiency Virus-Infected Adults
Authors: None International Collaboration on HIV and Cancer
Journal: JNCI Journal of the National Cancer Institute (2000)

Background: The risk of Kaposi's sarcoma and non-Hodgkin's lymphoma is increased in people infected with the human immunodeficiency virus-1 (HIV). Highly active antiretroviral therapy (HAART) has been widely used by HIV-infected people in North America, Europe, and Australia since about 1997. Acquired immunodeficiency syndrome (AIDS) incidence and mortality rates have fallen markedly in association with the use of HAART, but its impact on the incidence of cancer in HIV-infected people is less clear. Methods: Cancer incidence data from 23 prospective studies that included 47 936 HIV-seropositive individuals from North America, Europe, and Australia were collated, checked, and analyzed centrally. Adjusted incidence rates (expressed as number of cancers per 1000 person-years) for Kaposi's sarcoma, non-Hodgkin's lymphoma, Hodgkin's disease, cervical cancer, and 20 other cancer types or sites were calculated. Rate ratios were estimated, comparing incidence rates from 1997 through 1999 with rates from 1992 through 1996, after adjustment for study, age, sex, and HIV transmission group. All statistical tests were two-sided. Results: For the period from 1992 through 1999, 2702 incident cancers were reported in 138 148 person-years of observation, and more than 90% of them were either Kaposi's sarcoma or non-Hodgkin's lymphoma. The adjusted incidence rate for Kaposi's sarcoma declined from 15.2 in 1992 through 1996 to 4.9 in 1997 through 1999 (rate ratio = 0.32; 99% confidence interval [CI] = 0.26–0.40; based on 1489 and 190 cases, respectively; P<.0001). The incidence rates for non-Hodgkin's lymphoma also declined, from 6.2 to 3.6 (rate ratio = 0.58; 99% CI = 0.45–0.74; based on 623 and 134 cases, respectively; P<.0001). Among the lymphomas, the rate ratios were 0.42 (99% CI = 0.24–0.75) for cerebral lymphoma, 0.57 (99% CI = 0.39–0.85) for immunoblastic lymphoma, and 1.18 (99% CI = 0.48–2.88) for Burkitt's lymphoma (χ22 for heterogeneity = 6.2; P = .05). There was no statistically significant change in the incidence rates for Hodgkin's disease (rate ratio = 0.77; 99% CI = 0.32–1.85; based on 38 and 12 cases, respectively; P = .4) or for cervical cancer (rate ratio = 1.87; 99% CI = 0.77–4.56; based on 19 and 17 cases, respectively; P = .07). The adjusted incidence rate for all other cancers combined was 1.7 in each time period (rate ratio = 0.96; 99% CI = 0.62–1.47; based on 126 and 54 cases, respectively). Conclusions: Since the widespread use of HAART, there have been substantial reductions in the incidence Kaposi's sarcoma and non-Hodgkin's lymphoma in HIV-infected people but, so far, no substantial change in the incidence of other cancers.
Coming to “Grp(s)” with Senescence in the Alveolar Epithelium
Authors: Nichelle I. Winters, Jonathan A. Kropski
Journal: American Journal of Respiratory and Critical Care Medicine (2019)

triple-combination modulator therapy, which has shown greater efficacy than either dual combination and has been approved by the U.S. Food and Drug Administration.With the approval of the triple-combination drug, 90% of patients with CF will be eligible for a CFTR modulator (13).It is plausible that in the not-too-distant future, most infants diagnosed with CF will begin a highly effective CFTR modulator, such as the triple-combination treatment, shortly after birth, and continue receiving it indefinitely.This possibility highlights the continuing need for postmarketing observational analyses, such as this one by Burgel and colleagues, as we know relatively little about the long-term efficacy or safety of any CFTR modulator.
Dasatinib (SPRYCEL®) Efficacy and Safety in Patients (pts) with Chronic Myelogenous Leukemia in Lymphoid (CML-LB) or Myeloid Blast (CML-MB) Phase Who Are Imatinib-Resistant (Im-r) or -Intolerant (Im-i).
Authors: Giovanni Martinelli, A. Hochhaus, S. Coutre, J.F. Apperley, N. Shah, A. Gollerkeri, P. Agarwal, O.G. Ottmann
Journal: Blood (2006)
成人T細胞白血病(ATL)における共通ガンマ鎖受容体ファミリー(ガンマc:CD132)の病理学的役割:インターロイキン-4Rアルファ(CD124)およびインターロイキン-7Rアルファ(CD127)の発現
Authors: Yamada Y, Tsuruda K, Sugahara K, Harasawa H, Baba K, Mori N, Maeda T, Tomonaga M, Kamihira S
Journal: Blood (2000)
A longitudinal study of anthracycline cardiotoxicity in pediatric Ewing sarcoma.
Authors: Tanya Renae Brown, Chodchanok Vijarnsorn, James Potts, Ruth Milner, George Sandor, Christopher Fryer
Journal: Journal of Clinical Oncology (2012)

9529 Background: Trends in cardiac function over time have not been previously described in Ewing sarcoma. Our cohort is unique as all the cardiac evaluations occurred systematically in one tertiary cardiology unit during a 28 year period. Objectives: 1.To evaluate the cardiac functional trends in the cohort at baseline, during treatment and in surveillance. 2.To evaluate the risk factors associated with cardiac toxicity. Design: Received ethics approval for a retrospective chart review of all patients less than 17 years, diagnosed with Ewing sarcoma from 1978-2006, treated initially at British Columbia Children’s Hospital . Methods: There was complete data on 71/79 eligible patients. Echocardiograms were recorded at 5 time points: pre treatment, worst function during treatment, on therapy completion, worst function during surveillance and the most recent echocardiogram. Cardiac toxicity was graded using CTCAE v 4.0. The statistical analysis with SAS software v 9.2 calculated the chi square and odds ratios to explore a possible association between exposure and outcome. Results: Median age at diagnosis 11.1 yrs (2.2-16.1 yrs), 52% female, metastatic in 17, overall survival 74% at 10yrs. A total of 397 echocardiograms were performed with 244 (61%) being normal and 153 (39%) being abnormal. The median cumulative dose of anthracyclines was 365mg/m 2 . Grade 1-5 cardiomyopathy occurred in 42 (59%) patients. Grade 3-5 toxicity occurred in 11 (15%) patients on chemotherapy completion increasing to 23 (32%) 120 months post diagnosis. The median time to the worst cardiac function was 51months (2-183). Four of 19 (20%) deaths were cardiac related including 2/3 cardiac transplants. Conclusions: Symptomatic cardiac toxicity increased from 20% noted in our earlier Ewings cohort (Kakader et al. 1997) to 32% with longitudinal evaluation assessments. Significant and progressive cardiac toxicity occurred after completion of chemotherapy.
Use of Pharmacogenetics and Clinical Factors To Predict the Maintenance Dose of Warfarin.
Authors: B. F. Gage, C. S. Eby, J. A. Johnson, M. J. Rieder, P. M. Ridker, A. E. Rettie, C. Aquilante, P. E. Milligan, S. Marsh, D. Voora, T. Langaee, D. L. Veenstra, E. Birman-Deych, R. Glynn, D. A. Nickerson, H. L. McLeod
Journal: Blood (2005)
The Plot Thickens: The Emerging Role of Matrix Viscosity in Cell Mechanotransduction
Authors: Marco Cantini, Hannah Donnelly, Matthew J. Dalby, Manuel Salmeron‐Sanchez
Journal: Advanced Healthcare Materials (2019)

Cell mechanotransduction is an area of intense research focus. Until now, very limited tools have existed to study how cells respond to changes in the extracellular matrix beyond, for example, mechanical deformation studies and twisting cytometry. However, emerging are a range of elastic, viscoelastic and even purely viscous materials that deform and dissipate on cellular length and timescales. This article reviews developments in these materials, typically translating from 2D model surfaces to 3D microenvironments and explores how cells interact with them. Specifically, it focuses on emerging concepts such as the molecular clutch model, how different extracellular matrix proteins engage the clutch under viscoelastic-stress relaxation conditions, and how mechanotransduction can drive transcriptional control through regulators such as YAP/TAZ.
BCR/ABL→STAT5 Pathway Stimulates Helix-Loop-Helix Id-1 Protein To Enhance the MMP9 - Dependent Invasiveness of Leukemia Cells.
Authors: Margaret Nieborowska-Skorska, Grazyna Hoser, Maciej Malecki, Mariusz Wasik, Tomasz Skorski
Journal: Blood (2004)
Response to: ‘Comment on ‘Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial’ by Tanaka <i>et al</i>’ by Berkhout <i>et al</i>
Authors: Yoshiya Tanaka, Koji Oba, Tsutomu Takeuchi
Journal: Annals of the Rheumatic Diseases (2019)

We would like to thank Berkhout et al for their comments on the absence of an association between serum TNF concentrations and treatment response to infliximab in our paper.1

First, reliability of the obtained results on the serum levels of TNF in the study should be firmly confirmed, because the quality control of the assessments was stringently managed by the laboratory company who assessed …
The Level of AKT Phosphorylation on Threonine 308 but Not on Serine 473 Is Associated with High-Risk Cytogenetics and Predicts Poor Overall Survival in Acute Myeloid Leukemia.
Authors: Nathalie Gallay, Cédric Dos Santos, Lise Cuzin, Marina Bousquet, Violaine Simonnet Gouy, Claire Chaussade, Michel Attal, Bernard Payrastre, Cecile Demur, Christian Recher
Journal: Blood (2008)
Abstract 16428: Cumulative Psychosocial Stress and Incident Type II Diabetes in Older Women Participating in the Women’s Health Study
Authors: Jonathan Z Butler, Natalie Slopen, Manickavasagar V Moorthy, David R Williams, Tiffany M Powell-Wiley, Aruna Pradhan, Julie Buring, Nisha Parikh, Michelle A Albert
Journal: Circulation (2018)

Introduction: Chronic and acute stressors, referred to as “cumulative stress”, is associated with higher cardiovascular disease (CVD) risk. However, the relationship between cumulative stress and i...
TNF-a Polymorphism Modulates the Outcome of Multiple Myeloma Patients Treated with Bortezomib
Authors: Gabriele Buda, Alessandro Martino, Valentina Maggini, Enrico Orciuolo, Sara Galimberti, Massimo Gentile, Marino Brunori, Fortunato Morabito, Anna Maria Rossi, Mario Petrini
Journal: Blood (2008)
Endoscopic management of Wirsungocele with recurrent acute pancreatitis
Authors: Ronald L. Y. Cheung, Shannon M. Chan, Hon C. Yip, Anthony Y. B. Teoh
Journal: Endoscopy (2019)

Cystic dilatation of the terminal ventral main pancreatic duct was first termed Wirsungocele in 2004 following an incidental finding [1]. The association between Wirsungocele and recurrent acute pancreatitis was first reported by Gupta et al. [2]. A potential etiology has been proposed involving dysfunction of the autonomic innervation of the sphincter of Oddi, causing non-coordination and functional obstruction at the papillary orifice, resulting in Wirsungocele [3]. However, the definite pathophysiological mechanism for formation of Wirsungocele and the association with recurrent acute pancreatitis remain uncertain. We describe here a case of the youngest patient diagnosed with Wirsungocele with recurrent acute pancreatitis reported to date in the literature.
Synergistic effect of TELCYTA™ (TLK286) in combination with paclitaxel, doxorubicin, carboplatin, oxaliplatin, cisplatin, docetaxel, gemcitabine and iressa in human cancer cells.
Authors: Hua Xu, Soon-Young Namgoong, Elena Roth, Gail L. Brown, James G. Keck
Journal: Cancer Research (2004)

2008  TLK286 is a novel glutathione analog cancer prodrug that has shown significant antitumor activity in multiple Phase 2 clinical trials in ovarian, breast, non-small cell lung and colorectal cancers. TLK286 is activated by glutathione S-transferase P1-1 (GST P1-1), an enzyme upregulated in many types of cancer and often over-expressed in tumor cells resistant to chemotherapeutic agents. Since the clinical toxicity profile observed with TLK286 is non-overlapping with standard chemotherapeutics and TLK286 lacks cross resistance to many standard chemotherapy agents, TLK286 is a potential candidate for drug combination regimens. We have now tested TLK286 in combination with standard anticancer drugs in multiple human cancer cell lines. TLK286 in combination with paclitaxel, doxorubicin or carboplatin showed marked enhancement of cytotoxicity when compared to either agent alone in OVCAR3 cells. The synergy was greatest for TLK286 and carboplatin, with maximum or near maximum activity observed under all conditions examined. In human colon cancer cells HT-29 and DLD-1, the combination of TLK286 and oxaliplatin synergistically inhibited cell growth in a sequence-independent manner. In human lung cancer A549 cells, TLK286 was synergistic with cisplatin or paclitaxel at inhibiting cell proliferation. In the breast cancer cell line MCF-7, treatment of TLK286 in combination with docetaxel or gemcitabine resulted in significantly enhanced inhibition of cell growth. In the MX-1 human breast cancer cell line, the combination of TLK286 and Iressa showed an increased activity when compared to the agents alone. These data support the further study of TLK286 based combination chemotherapy regimens.
Effects of lower body negative pressure and volume loading on transmitral flow velocity pattern by pulsed doppler echocardiography.
Authors: Takuya Tsukamoto, Motoshi Takeuchi, Hisashi Fukuzaki
Journal: Circulation (1989)

The transmitral flow (TMF) profile was studied in 18 patients with ischemic heart disease and in 4 patients with chest pain syndrome in order to clarify the dependency of preload alteration on the pattern of TMF. Pulsed Doppler echocardiography with simultaneous measurement of right-sided cardiac catheterization and M-mode echocardiography during lower body negative pressures (LBNP 0, -10 mmHg, -20 mmHg) and Dextran infusions (Dex 100 ml, 200 ml) were used in the study. After LBNP, peak velocities in rapid filling (peak R) (cm/sec) decreased (control; 68.3±13.9, LBNP -10 mmHg; 59.8±15.2, p<0.01, LBNP -20 mmHg; 55.2±11.0, p<0.01) and the integrals in the first half phase in rapid filling (IR1) (cm) also decreased (control; 4.0±0.8, LBNP -10 mmHg; 3.4±0.9, LBNP -20 mmHg; 3.2±0.9, p<0.05). During Dextran infusion, peak R (cm/sec) increased (control; 53.5±7.5, Dex 100 ml; 57.8±10.0, p<0.05, Dex 200 ml; 60.4±10.6, p< 0.01) as did IR1 (cm) (control; 3.2±1.1, Dex 100 ml; 3.8±1.0, p<0.01, Dex 200 ml; 4.2±1.3, p<0.01). In conclusion, changes in preload may alter the peak velocity and the first half integral in left ventricular rapid filling depending on the pattern of transmitral flow velocity.
Abstract 12547: Resource Use and Outcomes of Children With Congenital Heart Disease Admitted to the Hospital From 2003 to 2016
Authors: Jonathan B Edelson, Joseph W Rossano, Heather Griffis, William Quarshie, Chitra Ravishankar, Matthew J O’Connor, Christopher Mascio, Laura A Mercer-Rosa, Andrew C Glatz, Kimberly Y Lin
Journal: Circulation (2019)

Introduction: Limited data exist on the epidemiology and resource utilization of congenital heart disease (CHD) related admissions among pediatric patients. We assessed the frequency, complexity, a...
Anti-Leukemia Activity of Alloreactive NK Cells in Haploidentical HSCT in Pediatric Patients: Re-Defining the Role of Activating and Inhibitory KIR
Authors: Daniela Pende, Stefania Marcenaro, Michela Falco, Stefania Martini, Maria Ester Bernardo, Daniela Montagna, Elisa Romeo, Myriam Martinetti, Rita Maccario, Maria Cristina Mingari, Lorenzo Moretta, Franco Locatelli, Alessandro Moretta
Journal: Blood (2008)
Underappreciated Bias Created by Measurement Error in Risk Factor Assessment—A Case Study of No Safe Level of Alcohol Consumption
Authors: Mary C. Vance, Tanner J. Caverly, Rodney A. Hayward
Journal: JAMA Internal Medicine (2019)

Our findings demonstrate that even after the FDA rejected an application to market piracetam as a new supplement ingredient, 3 the drug was nevertheless introduced into the marketplace.Despite FDA warning letters, 6 the products remain on the market.Until the law governing supplements is reformed such that products adulterated with drugs can be effectively removed from the market, clinicians should advise patients that supplements marketed as cognitive enhancers may contain prohibited drugs at supratherapeutic doses.
Breakthrough Hemolysis in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab: Results of a 52-Week Extension from Two Phase 3 Studies
Authors: Anita Hill, Caroline I. Piatek, Régis Peffault de Latour, Lily LL Wong, Richard A. Wells, Robert A. Brodsky, Jin Seok Kim, Junichi Nishimura, Philip Kuriakose, Rodrigo Pavani, Peng Liu, Stephan Ortiz, Hubert Schrezenmeier, Jong-Wook Lee, Austin Kulasekararaj
Journal: Blood (2019)
Functional Characterization of Aspergillus Fumigatus Specific T-Cells Clones.
Authors: Thomas Lehrnbecher, Ulrike Koehl, Emmanuel Roilides, Maria Simitsopoulou, Mitra Hanisch, Lars Tramsen, Jean-Paul Latge, Max S. Topp, Hermann Einsele, Thomas Klingebiel, Olaf Beck
Journal: Blood (2005)
Hepcidin Expression Is Correlated with Erythropoietic Indexes and Non-Transferrin-Bound Iron Levels in Patients with Thalassemia Major.
Authors: Antonios Kattamis, Ioannis Papassotiriou, Danai Palaiologou, Kalliopi Drakaki, Filia Apostolopoulou, George Papanikolaou
Journal: Blood (2005)
Review of Current Policy Strategies to Reduce US Cancer Drug Costs
Authors: Angela K. Green, Jennifer A. Ohn, Peter B. Bach
Journal: Journal of Clinical Oncology (2019)

Article Tools REVIEW ARTICLES Health Services and Outcomes Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.19.01628 Journal of Clinical Oncology - published online before print December 5, 2019 PMID: 31804856 Review of Current Policy Strategies to Reduce US Cancer Drug Costs Angela K. Green, MD, MSc1xAngela K. GreenSearch for articles by this author; Jennifer A. Ohn, MPH1xJennifer A. OhnSearch for articles by this author; and Peter B. Bach, MD, MAPP1xPeter B. BachSearch for articles by this author Show More 1Memorial Sloan Kettering Cancer Center, New York, NY https://doi.org/10.1200/JCO.19.01628 First Page Full Text PDF Figures and Tables © 2019 by American Society of Clinical Oncology
Prevention of graft failure by an anti human leukocyte functional antigen 1 monoclonal antibody in hla mismatched bone marrow transplantation
Authors: A. Fischer, C. Griscelli, S. Blanche, F. Le-Deist, F. Veber, M. Lopez, M. Delaage, D. Olive, C. Mawas, G. Janossy
Journal: The Lancet (1986)
A Novel 2′-Deoxy-2′-Fluoro (2′F-ANA) Ribose Modification Significantly Enhances the Duration, and Efficiency, of Nucleic Acid Mediated Gene Silencing.
Authors: Anna Kalota, Lidia Karabon, Cezary S. Swider, Ekaterina Viazovkina, Mohamed Elzagheid, Masad J. Damha, Alan M. Gewirtz
Journal: Blood (2005)
Sulforaphane and PEITC Augment Activity of Conventional and Novel Anti-Myeloma Drugs
Authors: Jana Jakubikova, Jan Sedlak, Steffen Klippel, Merav Leiba, Yu-Tzu Tai, Teru Hideshima, Klaus Podar, Dharminder Chauhan, Noopur Raje, Paul G. Richardson, Kenneth C. Anderson, Constantine S. Mitsiades
Journal: Blood (2008)
rNAPc2, a Novel Inhibitor of Tissue Factor/Factor VIIa Complex, Suppresses Lung Metastasis and Synergizes with 5-FU or Bevacizumab in Mouse Models of Colorectal Cancer.
Authors: Jingsong Zhao, Gerard Aguilar, Steven R. Deitcher, Walter Funk, Arie Abo
Journal: Blood (2006)
Modulating the cobalt dose range to manipulate multisystem cooperation in bone environment: a strategy to resolve the controversies about cobalt use for orthopedic applications
Authors: Guanqi Liu, Xiaoshuang Wang, Xuan Zhou, Linjun Zhang, Jiaomei Mi, Zhengjie Shan, Baoxin Huang, Zhuofan Chen, Zetao Chen
Journal: Theranostics (2019)

The paradoxical effect of cobalt on biological processes has aroused controversy regarding the application of cobalt-based biomaterials in bone regeneration. Tuning the dose range of cobalt ions may be a valid strategy to resolve the controversies about cobalt use for orthopedic applications. Recent progress in bone biology has highlighted the effects of multisystem cooperation (especially of osteoimmune, skeletal, and vascular systems) on bone dynamics. Before the application of this dose-tuning strategy, a deeper understanding of its dose-dependent effect on the cooperation of osteoimmune, skeletal, and vascular systems is needed. However, due to the difficulties with investigating the interaction of multiple systems
Analysis of Immunogenetic Factors in Paroxysmal Nocturnal Hemoglobinuria Reveal Increased Frequency of IL-10 Low Secretor Genotype and Correlates with Induced IL-10 Production.
Authors: Giridharan Ramsingh, Zachary Nearman, Chris Hung, Serio Bianca, Antonio Risitano, Jaroslaw Maciejewski
Journal: Blood (2006)